Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.

Sasaki T, Gannam ZTK, Kudalkar SN, Frey KM, Lee WG, Spasov KA, Jorgensen WL, Anderson KS.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2182-2188. doi: 10.1016/j.bmcl.2019.06.047. Epub 2019 Jun 26.

PMID:
31281023
2.

Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.

Kudalkar SN, Ullah I, Bertoletti N, Mandl HK, Cisneros JA, Beloor J, Chan AH, Quijano E, Saltzman WM, Jorgensen WL, Kumar P, Anderson KS.

Antiviral Res. 2019 Jul;167:110-116. doi: 10.1016/j.antiviral.2019.04.010. Epub 2019 Apr 26.

PMID:
31034849
3.

DRONE: Direct Tracking of DNA Cytidine Deamination and Other DNA Modifying Activities.

Sasaki T, Kudalkar SN, Bertoletti N, Anderson KS.

Anal Chem. 2018 Oct 16;90(20):11735-11740. doi: 10.1021/acs.analchem.8b01405. Epub 2018 Sep 28.

4.

Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection.

Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS.

Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8114-E8115. doi: 10.1073/pnas.1810136115. Epub 2018 Aug 10. No abstract available.

5.

From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.

Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E802-E811. doi: 10.1073/pnas.1717932115. Epub 2017 Dec 26. Erratum in: Proc Natl Acad Sci U S A. 2018 Mar 12;:.

6.

Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.

Chan AH, Lee WG, Spasov KA, Cisneros JA, Kudalkar SN, Petrova ZO, Buckingham AB, Anderson KS, Jorgensen WL.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9725-9730. doi: 10.1073/pnas.1711463114. Epub 2017 Aug 21.

7.

Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.

Kudalkar SN, Beloor J, Chan AH, Lee WG, Jorgensen WL, Kumar P, Anderson KS.

Mol Pharmacol. 2017 Apr;91(4):383-391. doi: 10.1124/mol.116.107755. Epub 2017 Feb 6.

8.

Assay of Endocannabinoid Oxidation by Cyclooxygenase-2.

Kudalkar SN, Kingsley PJ, Marnett LJ.

Methods Mol Biol. 2016;1412:205-15. doi: 10.1007/978-1-4939-3539-0_21.

9.

Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2.

Blobaum AL, Xu S, Rowlinson SW, Duggan KC, Banerjee S, Kudalkar SN, Birmingham WR, Ghebreselasie K, Marnett LJ.

J Biol Chem. 2015 May 15;290(20):12793-803. doi: 10.1074/jbc.M114.635987. Epub 2015 Mar 30.

10.

A role for catalase-peroxidase large loop 2 revealed by deletion mutagenesis: control of active site water and ferric enzyme reactivity.

Kudalkar SN, Njuma OJ, Li Y, Muldowney M, Fuanta NR, Goodwin DC.

Biochemistry. 2015 Mar 3;54(8):1648-62. doi: 10.1021/bi501221a. Epub 2015 Feb 23.

PMID:
25674665
11.

13-Methylarachidonic acid is a positive allosteric modulator of endocannabinoid oxygenation by cyclooxygenase.

Kudalkar SN, Nikas SP, Kingsley PJ, Xu S, Galligan JJ, Rouzer CA, Banerjee S, Ji L, Eno MR, Makriyannis A, Marnett LJ.

J Biol Chem. 2015 Mar 20;290(12):7897-909. doi: 10.1074/jbc.M114.634014. Epub 2015 Feb 2.

12.

Enhancing the peroxidatic activity of KatG by deletion mutagenesis.

Kudalkar SN, Campbell RA, Li Y, Varnado CL, Prescott C, Goodwin DC.

J Inorg Biochem. 2012 Nov;116:106-15. doi: 10.1016/j.jinorgbio.2012.08.002. Epub 2012 Aug 21.

PMID:
23018273

Supplemental Content

Loading ...
Support Center